Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. Show More...

  • Website https://www.esperion.com
  • Sector Healthcare
  • Industry Drug Manufacturers-Specialty & Generic
  • Last Quote 1.18 USD
  • Last Updated 14-07-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2002-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -6.85 -14.97 -16.25 -3.31 -2.22 -2.26 -3.33 -6.98 -7.54 -3.59 -9.69
    Dividends USD
    Payout Ratio % *
    Shares Mil 4.0 1.0 1.0 8.0 16.0 22.0 23.0 24.0 27.0 27.0 27.0
    Book Value Per Share * USD 5.43 2.47 13.17 11.27 10.57 4.91 2.49 -1.82
    Free Cash Flow Per Share * USD -0.85 -2.09 -1.79 -1.78 -4.9 -5.82 -1.85
    Return on Assets % -44.28 -496.27 -247.4 -60.95 -32.82 -22.69 -27.73 -63.85 -95.81 -54.3 -126.31
    Financial Leverage (Average) 1.33 1.06 1.07 1.03 1.07 1.14 1.81 10.75
    Return on Equity % -54.59 -159.43 -35.04 -23.66 -29.07 -70.56 -124.65 -196.16 -421.26
    Return on Invested Capital % -47.73 -153.71 -33.2 -22.91 -28.53 -70.07 -124.59 -174.27 -381.36
    Interest Coverage -17.74 -6.9 -26.85 -133.72 -94.74 -198.41 -842.37 -10.97 -20.38
    Current Ratio 9.18 1.39 0.42 14.42 19.44 38.11 13.7 6.15 2.22 3.2 2.35
    Quick Ratio 9.09 1.17 0.38 14.29 19.28 37.74 13.57 6.04 2.11 3.04 2.14
    Debt/Equity 0.2 0.03 0.010 0.06